Drug Discovery

Grid Therapeutics signs exclusive license agreement to develop novel immuno-oncology antibody

Grid Therapeutics has signed an exclusive license agreement with Duke University to develop the first human derived antibody as a targeted immunotherapy for cancer.

Evotec completes Aptuit acquisition

German company Evotec has completed the acquisition of US-based Aptuit.

Vicarius Pharma secures $21.8m financing

Vicarius Pharma has secured a CHF21m ($21.8m) investment through a Series A preferred stock financing from private investors.

Oxford BioMedica announces collaboration for gene and cell therapy manufacturing

A new consortium, led by Oxford BioMedica, will take part in a two-year, £2m project focused on gene and cell therapy manufacturing.

Peregrine Pharmaceuticals cuts 20% of workforce to reduce costs

Peregrine Pharmaceuticals has cut down its workforce by up to 20%, as part of its efforts to decrease costs and achieve overall profitability.

Tissue Regenix acquires CellRight Technologies

UK-based regenerative medical company Tissue Regenix Group has completed the acquisition of CellRight Technologies, a US-based specialist in regenerative osteoinductive bone scaffolds.

Takeda, Cardurion Pharmaceuticals form cardiovascular development partnership

Takeda Pharmaceutical and Cardurion Pharmaceuticals have created a new cardiovascular development partnership.

Researchers develop new drug that could treat and limit Parkinson’s disease

Binghamton University researchers have developed a new drug that could possibly limit the progression of Parkinson’s disease and also provide better symptom relief.

Bristol-Myers Squibb to acquire IFM Therapeutics to expand cancer pipeline

Bristol-Myers Squibb has agreed to acquire Boston-based IFM Therapeutics for an upfront payment of $300m to strengthen its oncology pipeline.